Would it be worth it???? Mycrludex and Replicor

hoimes

Would it be worth it????

The truth is Mycrludex and Replicor are the best options for curing HBV. Due to our NDA I can not release all the details, but I can assure you that both companies are at least 18-36 months away from making market advancements.....However for the scientific mind both drugs can be manufactured in Japan or Switzerland. Your minimum investment would be between 25-50K.
The very best option as a sufferer would be to combine an anti-viral, with short term interferon (to ensure cell turn over) as Mycrludex only blocks reinfection. The interferon would accelerate the cell turnover, the anti-viral will lower HBV-DNA, and the Replicor would promote the HBV anti-body.
The whole process would be less then 6 months.

Would all these companies co-operate on a joint venture NOT likely...Could it be successfully managed as an individual...yes.
Would you need the support of a good chemist...yes
Would your Dr. support you....NOT likely
Would you be cured...yes

cshbv

Very worth it. 这个是目前唯一有可能完全清除病毒的方法。
Bing 直接翻译.

真理就是 Mycrludex 和 Replicor 是治疗乙型肝炎病毒的最佳选择。由于对我们保密协议 (nda) 我不能放的详细信息，但我可以向你保证，两家公司都至少 18-36 个月远离制作市场进步 … …但是科学精神这两种药物可以在日本或瑞士制造。您最小的投资将是 25-50 K 之间。
作为患者非常最佳选项将结合短期干扰素抗病毒 (以确保细胞翻），Mycrludex 仅阻止再感染。干扰素会加速细胞周转、 抗病毒会降低乙肝病毒 DNA，和 Replicor 将推动乙型肝炎病毒抗体。
整个过程将更少当时的 6 个月。

一项关于共同合作，这些公司都敢不太可能...可能它成功地进行管理作为个人 … … 是的。
你需要一个好的化学家 … … 的支持是
你博士会支持你 … …。不太可能
将您可治愈 … … 是的

乙肝无罪1

看着这个消息 好像是 内部员工的邮件么  看来 这两个药已经有跟干扰素或者核苷联合治疗了 好 不错不错

MiddleAgeMan

Replicor is in phase II

Mycrludex is in phase I. Mycrludex phase II is scheduled in summer 2012.

they all have the ability to block the re-infection of hepatocyte, and this is the chance to cure the HBV. Now, the antiviral drug only blocks the replication of hbvdna, which does not CURE the HBV.

Dan

StephenW

回复 MiddleAgeMan 的帖子


According to Studyforhope of MedHelp:

Mycrludex blocks the entry of HB virus into the liver cells - so it is effective against new infection or re-infection.

REP9AC blocks the release of HbsAg particles from an infected liver cell, but it does not block the release of new virions (Dane particles) from the infected liver cell.

So we need to wait for clinical trials to see if the blocking of release of HBsAg particles will lead to  full immune control of HBV.

Good to be optimistic but not too optimistic.

据MedHelp Studyforhope：

Mycrludex阻止乙肝病毒进入肝细胞- 因此，它是有效预防新的感染或再感染。

REP9AC阻止从被感染的肝细胞释放HBsAg颗粒，但它不会阻止从被感染的肝细胞释放
新的病毒颗粒（Dane颗粒）。

因此，我们需要等待临床试验，看看阻断HBsAg颗粒释放将导致全乙肝免疫控制。


乐观好，但不能过于乐观。

cshbv

MiddleAgeMan 发表于 2011-11-10 03:01
Replicor is in phase II

Mycrludex is in phase I. Mycrludex phase II is scheduled in summer 2012.

According to hep.org drug watch, both are in phase I. Are they not? If Rep9ac is in phase ii, then it's better.

cshbv

又看了下replicor的网站，rep9ac貌似正在同时进行一期和二期临床。